Kenan ÇADIRCI

Dr. Kenan ÇADIRCI


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2023 in Foods
Verified
Journal Article
Open access
PDF file
EEElif Ekiz
Elif Ekiz
EOEmel Oz
Emel Oz
A. M. Abd El-AtyA. M. Abd El-Aty
A. M. Abd El-Aty
Charalampos ProestosCharalampos Proestos
Charalampos Proestos
Charles BrennanCharles Brennan
Charles Brennan
FOFatih Oz
Fatih Oz
Ganoderma lucidum is a medicinal mushroom that has been traditionally used in Chinese medicine for centuries. It has been found to have a wide range of medicinal properties, including antioxidant, anti-inflammatory, and immune-boosting effects. Recent research has focused on the potential benefits of G. lucidum in treating metabolic disorders such as diabetes and obesity, as well as its possible role in preventing and treating infections caused by the coronavirus. Triterpenoids are a major group of bioactive compounds found in G. lucidum, and they have a range of biological activities, including anti-inflammatory and antioxidant properties. These compounds have been found to improve insulin sensitivity and lower blood sugar levels in animal models of diabetes. Additionally, G. lucidum polysaccharides have been found to reduce bodyweight and improve glucose metabolism in animal models of obesity. These polysaccharides can also help to increase the activity of certain white blood cells, which play a critical role in the body’s immune response. For coronavirus, some in vitro studies have shown that G. lucidum polysaccharides and triterpenoids have the potential to inhibit coronavirus infection; however, these results have not been validated through clinical trials. Therefore, it would be premature to draw any definitive conclusions about the effectiveness of G. lucidum in preventing or treating coronavirus infections in humans.

6 April 2020 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
KÇKenan ÇADIRCI
Kenan ÇADIRCI
ÖÖÖzlem Özdemir
Özlem Özdemir
Hasan TurkezHasan Turkez
Hasan Turkez
AMAdil Mardi̇nOğlu
Adil Mardi̇nOğlu
Background/aim: Aspartame (APM, L-aspartyl-L-phenylalanine methylester) is a low-calorie, nonsaccharide artificial sweetener widely used in foods and beverages. When metabolized by the body, APM is broken down into aspartic acid, phenylalanine amino acids, and a third substance, methanol. Since the amino acid phenylalanine serves as a neurotransmitter building block affecting the brain, and methanol is converted into toxic formaldehyde, APM has deleterious effects on the body and brain. Thus, its safety and, toxicity have been the subjects of concern ever since it was first discovered. Although many studies have been performed on it, due to the presence of conflicting data in the literature, there are still numerous question marks concerning APM. Therefore, the safety of aspartame was tested using in vitro methods. Materials and methods: We aimed to evaluate the in vitro cytotoxic effects by using 3-(4,5-dimetylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate dehydrogenase release tests, genotoxic damage potential by using chromosome aberration (CA) assay, and antioxidant/oxidant activity by using total antioxidant capacity (TAC) and total oxidative stress (TOS) analysis in primary human whole blood cell cultures. Results: The results of the MTT test showed that APM led to significant decreases in cell viability in a clear concentration-dependent manner. Moreover, an increase in CA frequency was found in the cells treated with APM. However, APM treatments did not cause any significant changes in TAC and TOS levels in whole blood cultures. Conclusion: Overall, the obtained results showed that APM had genotoxicity potential and a concentration-dependent cytotoxic activity in human blood cells.

19 January 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
Hasan TurkezHasan Turkez
Hasan Turkez
Ivana CacciatoreIvana Cacciatore
Ivana Cacciatore
LMLisa Marinelli
Lisa Marinelli
EFErika Fornasari
Erika Fornasari
MAMehmet Enes ARSLAN
Mehmet Enes ARSLAN
AMAdil Mardinoglu
Adil Mardinoglu
So far, there is no effective disease-modifying therapies for Alzheimer’s Disease (AD) in clinical practice. In this context, glycine-L-proline-L-glutamate (GPE) and its analogs may open the way for developing a novel molecule for treating neurodegenerative disorders, including AD. In turn, this study was aimed to investigate the neuroprotective potentials exerted by three novel GPE peptidomimetics (GPE1, GPE2, and GPE3) using an in vitro AD model. Anti-Alzheimer potentials were determined using a wide array of techniques, such as measurements of mitochondrial viability (MTT) and lactate dehydrogenase (LDH) release assays, determination of acetylcholinesterase (AChE), α-secretase and β-secretase activities, comparisons of total antioxidant capacity (TAC) and total oxidative status (TOS) levels, flow cytometric and microscopic detection of apoptotic and necrotic neuronal death, and investigating gene expression responses via PCR arrays involving 64 critical genes related to 10 different pathways. Our analysis showed that GPE peptidomimetics modulate oxidative stress, ACh depletion, α-secretase inactivation, apoptotic, and necrotic cell death. In vitro results suggested that treatments with novel GPE analogs might be promising therapeutic agents for treatment and/or or prevention of AD.

1 March 2025 in The Aging Male
Verified
Journal Article
Open access
MBMuharrem Bayrak
Muharrem Bayrak
KKKamber Kaşali
Kamber Kaşali
MGMerve Güner
Merve Güner
KÇKenan ÇADIRCI
Kenan ÇADIRCI
AKAdil Furkan Kılıç
Adil Furkan Kılıç
DBDogan Nasır Binici
Dogan Nasır Binici
Type 2 diabetes mellitus (T2DM) is a common chronic disease in the elderly. Comorbidities, especially neuropathy and retinopathy, significantly increase fall risk in this group. This study aimed to identify fall risk factors in older adults with T2DM. From January to June 2024, 242 T2DM patients aged 65 and older were followed at the internal medicine outpatient clinic. Fall risk was assessed using the Performance Oriented Mobility Assessment (POMA), Hendrich II Fall Risk Model (HIIFRM), Barthel Activities of Daily Living Index, and Clinical Frailty Scale (CFS). Among the patients (median age = 70 years), 41.3% had experienced at least one fall in the previous year. Factors, such as age and diabetes duration were associated with falls. Notably, hypoglycemia (aPR: 1.90, p = 0.017), polypharmacy (aPR: 2.39, p = 0.004), osteoarthritis (aPR: 2.48, p = 0.017), (aPR: 1.70, p = 0.025), and malnutrition (aPR: 1.90, p = 0.007) were independently associated with fall risk. Fall risk in elderly outpatients with T2DM was linked to various factors, including hospitalization, malnutrition, osteoarthritis, polypharmacy, neuropathy, and hypoglycemia. To mitigate this risk, patient-specific care plans are recommended.

15 June 2023 in International Journal of Food Science and Technology
Verified
Journal Article
Open access
EOEmel Oz
Emel Oz
ASAysegul Simsek
Aysegul Simsek
MSMelih Simsek
Melih Simsek
NTNihal Tuncer
Nihal Tuncer
MBMuharrem Bayrak
Muharrem Bayrak
FOFatih Oz
Fatih Oz
Summary: Microbiota plays an essential role in human development and body homeostasis. Individual and environmental variables influence the diversity of microbiota, which performs crucial biochemical activities in the human body and influences health status and disease in later years. Many diseases in adulthood may be prevented or treated if the relationship between the microbiome, nutrition, especially the immune system, and growth and development could be fully understood. For a healthy gut microbiota, the diet‐related changes in the core microbiota must be long‐lasting, achieving permanence in microbiota change. This process is possible by maintaining a sustainable diet and adhering to this diet for a long time. Therefore, this study reviewed the relationship between nutrition, microbiota, and various life‐threatening diseases.

17 April 2021 in Acta Clinica Belgica
Verified
Journal Article
Closed access
MBMuharrem Bayrak
Muharrem Bayrak
KÇKenan ÇADIRCI
Kenan ÇADIRCI
Associations of depression, dementia, and poor life quality with mortality of COVID-19have not been studied yet. We aimed to identify the risk factors for mortality and analyze the associations wit...